Export to BibTeX Export to EndNoteNo evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study) (111 views)
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V
Mult Scler (ISSN: 1352-4585linking, 1477-0970electronic), 2016 Aug; 22(9): 1163-1173.
Abstract
BACKGROUND: A previous phase 2 trial has suggested that statins might delay brain atrophy in secondary progressive multiple sclerosis. OBJECTIVES: The objective of this study was to evaluate the effect of atorvastatin add-on therapy on cerebral atrophy in relapsing-remitting multiple sclerosis. METHODS: This randomised, placebo-controlled study compared atorvastatin 40 mg or placebo add-on therapy to interferon beta1b for 24 months. Brain magnetic resonance imaging, multiple sclerosis functional composite score, Rao neuropsychological battery and expanded disability status scale were evaluated over 24 months. RESULTS: A total of 154 patients were randomly assigned, 75 in the atorvastatin and 79 in the placebo arms, with a comparable drop-out rate (overall 23.4%). Brain atrophy over 2 years was not different in the two arms (-0.38% and -0.32% for the atorvastatin and placebo groups, respectively). Relapse rate, expanded disability status scale, multiple sclerosis functional composite score or cognitive changes were not different in the two arms. Patients withdrawing from the study had a higher number of relapses in the previous 2 years (P=0.04) and a greater probability of relapsing within 12 months. CONCLUSIONS: Our results suggest that the combination of atorvastatin and interferon beta1b is not justified in early relapsing-remitting multiple sclerosis and adds to the body of evidence indicating an absence of significant radiological and clinical benefit of statins in relapsing-remitting multiple sclerosis.
Affiliations ▼
*** IBB - CNR Affiliation
Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University of Naples, Italy robertalanzillo@libero.it roberta.lanzillo@unina.it.
National Research Council (CNR) Biostructure and Bioimaging Institute (IBB), Naples Multiple Sclerosis Centre, Italy.
Department of Neurology and Psychiatry, Sapienza University, Italy.
Department of NEUROFARBA, University of Florence, Italy.
Department of Public Health and Clinical and Molecular Medicine, University of Cagliari, Italy.
Multiple Sclerosis Regional Center, Azienda Ospedaliera "Antonio Cardarelli", Italy.
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy.
IRCCS Neuromed-Pozzilli (IS), Italy.
Neurology Unit, Fondazione Istituto San Raffaele "G. Giglio", Italy.
Department of Biomedical Advanced Sciences, Federico II University, Italy.
IDC Hermitage Capodimonte, Italy.
Dimensione Ricerca S.r.l., Italy. |
Details ▼
Impact factor: 4.863, 5-year impact factor: 4.276
Paper type: Journal Article,
Keywords: Atorvastatin, Brain Atrophy, Interferon Beta1b, Multiple Sclerosis,
Url: Not available. |
References ▼
Related activities ▼
Related papers ▼
Related bibliography ▼
<=2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 ALL YEARS
Sort by: date ▼▲ title ▲ ▼ journal ▲ ▼ authors ▲ ▼ impact factor ▲ ▼* Brain atrophy in Relapsing-remitting multiple sclerosis patients treated with interferon-beta and atorvastatin (The ARIANNA study) (102 views)Lanzillo R, Quarantelli M, Veria V, Orefice G, Marrosu MG, Trojano M, Amato MP, Francia AM, Florio C, Tedeschi G, Bellantonio P, Annunziata P, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Pozzilli C, Morra VB
J Neurol (ISSN: 0340-5354, 1432-1459, 1432-1459electronic), 2014 May 31; 261(Suppl.1): S43-S43.
View Export to BibTeX Export to EndNote Upload PDF
* Brain atrophy in relapsing-remitting multiple sclerosis patients treated with interferon-beta and atorvastatin (The ARIANNA study) (81 views)Lanzillo R, Quarantelli M, Veria V, Orefice G, Marrosu MG, Trojano M, Amato MP, Francia AM, Florio C, Tedeschi G, Bellantonio P, Annunziata P, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Pozzilli C, Morra VB
Eur J Neurol (ISSN: 1351-5101, 1468-1331electronic), 2014 May; 21(S.I.Suppl.1): 58-58.
View Export to BibTeX Export to EndNote Upload PDF
* Is brain atrophy progression in RR-MS slowed by the association off atorvastatin and interferon beta-1a? Preliminary results from an open-label, randomized, clinical study (35 views)Quarantelli M, Orefice G, Prinster A, Lanzillo R, Salvatore P, Mallica C, Salvatore E, Brunetti A, Alfano B, Morra VB
Neurology (ISSN: 0028-3878, 1526-632x), 2008 Mar 11; 70(11): N/D-N/D.
View Export to BibTeX Export to EndNote Upload PDF
3 Records ( 0 excluding Abstracts and Conferences). Total impact factor: 15.996 ( 0 excluding Abstracts and Conferences). Total 5-year impact factor: 15.885 ( 0 excluding Abstracts and Conferences).
Your bibliography query: (([btitle, keywords, abstract] ATORVASTATIN AND [btitle, keywords, abstract] BRAIN AND [btitle, keywords, abstract] ATROPHY AND [btitle, keywords, abstract] INTERFERON)) AND NOT [id] = 53021
|
|
Last modified by Gennaro Angrisano on Wednesday 26 October 2016, 17:57:20
111 views. Last viewed on Wednesday 12 July 2017, 0:26:22
|
INCIPIT
ISTAPCA (784 views)
Euro-BioImaging
Instruct-IT
Fondazione Veronesi
Fondo Europeo Pesca (203 views)
INMiND (880 views)
PRIN (983 views)
eHealthNet (810 views)
Ponrec (761 views)
MFAG Grant (820 views)
